Class II · Moderate risk
DACARBAZINE 680 MG in 250 ml NS
Lack of Assurance of Sterility
FDA Drug Recalls
18,003 recalls, newest first
Class II · Moderate risk
Cytarabine 128 MG/250 ML D5W IVPB
Lack of Assurance of Sterility
Class II · Moderate risk
Cyclophosphamide 840 MG / 250 ML NS IVPB
Lack of Assurance of Sterility
Class II · Moderate risk
Cisplatin 40 MG / 500 ml NS IVPB WITH Mannitol 40 G
Lack of Assurance of Sterility
Class II · Moderate risk
Cisplatin 40 MG / 500 ml NS IVPB WITH Mannitol 40 G
Lack of Assurance of Sterility
Class II · Moderate risk
Cetuximab 335 Mg / 167.5 Ml Ivpb
Lack of Assurance of Sterility
Class II · Moderate risk
Carfilzomib 65 Mg in 50 Ml D5w Ivpb
Lack of Assurance of Sterility
Class II · Moderate risk
CARBOPLATIN 174 MG / 250ml NS IVPB
Lack of Assurance of Sterility
Class II · Moderate risk
Calcium Gluconate 1 Gm /100 Ml Nacl 0.9% Ivpb
Lack of Assurance of Sterility
Class II · Moderate risk
BORTEZOMIB 2.5 mg / 1 ML SQ SYRINGE
Lack of Assurance of Sterility
Class II · Moderate risk
Bleomycin 18 Units / 100 Ml Ns Ivpb
Lack of Assurance of Sterility
Class II · Moderate risk
Bevacizumab 784 Mg / 100 Ml Ns Ivpb
Lack of Assurance of Sterility
Class II · Moderate risk
Azacitidine 125 Mg / 5 Ml Sub-Q Syringe
Lack of Assurance of Sterility
Class II · Moderate risk
Avastin 630 Mg / 100 Ml 0.9% Nacl Ivpb
Lack of Assurance of Sterility
Class II · Moderate risk
Atezolizumab 1200 Mg / 250 Ml 0.9% Nacl
Lack of Assurance of Sterility
Class II · Moderate risk
ALIMTA 785 mg QS 100 ml 0.9% NACL IVPB
Lack of Assurance of Sterility
Class II · Moderate risk
ADO-TRASTUZUMAB 210 MG/250 ml NS
Lack of Assurance of Sterility
Class II · Moderate risk
Adcetris 96 MG/100 ML NS IVPB
Lack of Assurance of Sterility
Class II · Moderate risk
Abraxane 170 MG / 34 ML IVPB
Lack of Assurance of Sterility
Class II · Moderate risk
Oxytocin 60 units/1000 mL Lactated Ringers Intravenous Solution
Lack of Assurance of Sterility
Class III · Low risk
Testosterone Topical Solution 30mg of testosterone per pump…
Defective Container; actuator may improperly function and affect dose delivery.
Class II · Moderate risk
Robafen DM
CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Class I · High risk
Hydromorphone HCl in 0.9% sodium chloride
Incorrect Product Formulation; Firm's customer resource center (CRC) statement indicates that the product is sulfite free, however the product is produced with a raw material that contains sulfite
Class III · Low risk
Myorisan (isotretinoin capsules, USP)
Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.
Class II · Moderate risk
LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.